#8489. CORR Insights®: Which Bone-Modifying Agent is Associated with Better Outcomes in Patients with Metastatic Bone Disease from Lung Cancer? A Systematic Review and Network Meta-Analysis

January 2027publication date
Proposal available till 30-05-2025
4 total number of authors per manuscript5500 $

The title of the journal is available only for the authors who have already paid for
Journal’s subject area:
Medicine (all);
Surgery;
Places in the authors’ list:
place 1place 2place 3place 4
FreeFreeFreeFree
2350 $1200 $1050 $900 $
Contract №8489.1 Contract №8489.2 Contract №8489.3 Contract №8489.4
1 place - free (for sale)
2 place - free (for sale)
3 place - free (for sale)
4 place - free (for sale)

Abstract:
The study reviews the commonly used bone-modifying agents for the treatment of bone metastases to identify which one is the best option. The assessment revolves around the following indicators: overall survival, time to skeletal-related events, incidence of skeletal-related events, and likelihood of pain resolution.
Keywords:
Level of evidence; randomized controlled trial; patient outcome; efficacy; survival rate

Contacts :
0